Vaccination of cancer patients using tumor-associated antigens m

Details Vaccination of cancer patients using tumor-associated antigens m Vaccination of cancer patients using tumor-associated antigens m

1994-02-28

1995-12-26

Sidberry, Hazel F.

Drug, bio-affecting and body treating compositions

Involving sex selection or contraception

424 851, 4242771, 530351, 530828, A61K 4505, A61K 3900, C07K 14535, C07K 1455

Patent

active

054785561

ABSTRACT:
A breast cancer vaccine which comprises a mixture of tumor associated antigens (TAA) with low doses of recombinant interleukin-2 (IL-2) and granulocyte-macrophage colony stimulating factor (GM-CSF).

REFERENCES:
patent: Re33071 (1989-09-01), Stjernholm
patent: 5208323 (1993-05-01), Page et al.
Bystryn J. C., Cancer & Metastasis Rev. 9:81-91, 1990.
Colombo et al, Immunology Today 12(7): 249-250, 1991.
Brandes et al, Cancer Res 52(13): 3796-3800, 1992.
Kohn et al, Int. J. Cancer 53:968-972, 1993.
Martensson et al, Toxic in Vitro 7(3):241-245, 1993.
Hellstrom et al, Ann. N.Y. Acad Sci 690:24-33, 1993.
Berd et al, Cancer Res 46(5) 2572-2577, 1986.
Cassel W. A., Murray D.R., Phillips H. S., "A Phase II Study on the Postsurgical Management of Stage II Malignant Melanoma with a Newcastle Disease Virus Oncolysate," Cancer 52:856-860, 1983.
Humphrey L. J., Taschler-Collins S., Goldfarb P. M., et al., "Adjuvant Immunotherapy for Melanoma," J. Surg. Oncol. 25:303-305, 1984.
Hoover H. C., Surdyke M. G., Dangel R. B., et al., "Prospectively Randomized Trial of Adjuvant Active Specific Immunotherapy for Human Colorectal Cancer," Cancer 55:1256-1243, 1985.
Morton D. L., "Adjuvant Immunotherapy of Malignant Melanoma: Status of Clinical Trials at UCLA," Int. J. Immunotherapy II(1):31-38, 1986.
Hersey P., Edwards A., Coates A., et al., "Evidence that treatment with vaccinia melanoma cell lysates (vmcl) may improve survival of patients with stage II melanoma," Cancer Immunol. Immunotherapy 25:257-265, 1987.
Mitchell M. S., Harel W., Kempf R. A., et al., "Active-Specific Immunotherapy for Melanoma," J. Clin. Oncol. 8:856-869, 1990.
Wallack M. K., Bash J., and Bartolucci A., "Improvement in Disease-free Survial of Melanoma Patients in Conjuction With Serologic Response in a Phase Ia/Ib Southeastern Cancer Study Group Trial of Vaccinia Melanoma Oncolysate," Am. Surg., 55:243-247, 1989.
Morton D. L., Nizze A., Famatiga E., et al., "Clinical Results of a Trial of Active Specific Immunotherapy With Melanoma Cell Vaccine and Immunomodulation in Metastatic Melanoma," Proc. Am. Assoc. Cancer Res. 30:383, 1989.
Hollinshead A., Stewart T. H. M., Takita H., et al., "Adjuvant Specific Active Lung Cancer Immunotherapy Trials," Cancer, 60:1249-1262, 1987.
Wiseman C., Rao S., Kennedy P., et al., "Clinical Responses In Autologous Active Specific Intralymphatic Immunotherapy (AASILI) Correlate With Augmentation Of CD4+ Peripheral Blood Lymphocytes (PBL)," Proc. Am. Soc. Clin. Oncol. 8:186 1989.
Livingston P., "Active Specific Immunotherapy in the Treatment of Patients with Cancer," Human Cancer Immunology II:401-423, 1991.
Dean J. H., McCoy J. L., Cannon G. B., et al., "Cell-Mediated Immune Responses of Breast Cancer Patients to Autologous Tumor-Associated Antigens," J. Nat'l Cancer Inst. 58:549-555 1977.
Flaherty L. E., Redman B. G., Chabot G. G., et al. "A Phase I-II Study of Dacarbazine in Combination With Outpatient Interleukin-2 in Metastatic Malignant Melanoma", Cancer 65:2471-2477, 1990.
Gianni A. M., Bregni M., Siena S., et al., "Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor Reduces Hematologic Toxicity and Widens Clinical Applicability of Hight-Dose Cyclophosphamide Treatment in Breast Cancer and Non-Hodgkin's Lymphoma," J. Clin, Oncol. 8:768-778, 1990.
Atzpodien J. and Kirchner H., "The Out-Patient Use of recombinant Human Interleukin-2 and Interferon Alfa-2b in Advanced Malignancies", Eur. J. Cancer 27:588-592, 1991.
Caligiuri, M. A., Murray C., Soiffer R. J., et al. "Extended Continuous Infusion Low-Dose Recombinant Interleukin-2 in Advanced Cancer: Prolonged Immunomodulation Without Significant Toxicity," J. Clin. Oncol. 9:2110-2119, 1991.
Figlin R. A., Belldegrun A., Moldawer N., et al., "Concomitant Administration of Recombinant Human Interleukin-2 and Recombinant Interferon alfa-2A: An Active Outpatient Regimen in Metastatic Renal Cell Carcinoma," J. Clin. Oncol., 10:414-421, 1992.
Sleijfer D. Th., Janssen R. A. J., Buter J., et al., "Phase II Study of Subcutaneous Interleukin-2 in Unselected Patients With Advanced Renal Cell Cancer on an Outpatient Basis," J. Clin. Oncol. 10:1119-1123, 1992.
Oren M. E. and Herberman R. B., "Delayed Cutaneous Hypersensitivity Reactions to Membrane Extracts of Human Tumour Cells," Clin. Exp. Immunol 9:45-56, 1971.

Affiliated with

Also associated with

Rating

Vaccination of cancer patients using tumor-associated antigens m does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Vaccination of cancer patients using tumor-associated antigens m, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vaccination of cancer patients using tumor-associated antigens m will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1367310